Neurogene Inc. (NGNE): who owns it and who trades it
As of Nov 16, 2026, NGNE insiders reported 17 open-market sales worth $1.1M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christine Mikail Cvijic (CFO), with $900K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Neurogene
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NGNE
113 funds and institutions reported NGNE shares worth $546M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Samsara Biocapital, LLC with 11.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 1.72M | 11.03% | $54M | No change |
| Casdin Capital, LLC | 1.55M | 9.92% | $48.6M | +9% |
| Redmile Group, LLC | 1.41M | 9.07% | $44.4M | -3% |
| Rtw Investments, LP | 1.36M | 8.75% | $42.8M | No change |
| EcoR1 Capital, LLC | 1.27M | 8.16% | $40M | No change |
| BlackRock, Inc. | 1.06M | 6.79% | $33.3M | +5% |
| Baker Bros. Advisors LP | 991,691 | 6.37% | $31.2M | No change |
| Balyasny Asset Management L.P. | 818,706 | 5.26% | $25.7M | +14% |
| Trails Edge Capital Partners, LP | 714,885 | 4.59% | $22.5M | -9% |
| Toronto Dominion Bank | 681,337 | 4.37% | $21.4M | No change |
| Vanguard Capital Management LLC | 536,525 | 3.44% | $16.9M | +4% |
| Jennison Associates LLC | 518,582 | 3.33% | $16.3M | -2% |
| Citadel Advisors LLC | 408,982 | 2.63% | $12.9M | +6% |
| Great Point Partners LLC | 352,180 | 2.26% | $11.1M | -30% |
| ArrowMark Colorado Holdings LLC | 342,453 | 2.20% | $10.8M | -35% |
| FMR LLC (Fidelity) | 295,561 | 1.90% | $9.3M | -23% |
| Geode Capital Management, LLC | 293,182 | 1.88% | $9.2M | +5% |
| State Street Corp | 224,322 | 1.44% | $7.1M | -28% |
| Franklin Resources Inc | 204,280 | 1.31% | $6.4M | New |
| Morgan Stanley | 191,724 | 1.23% | $6M | -33% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NGNE insiders reported $0 of open-market purchases and $1.1M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 4,200 | $36.13 | $152K | Form 4 |
| Jul 6, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 600 | $36.02 | $21.6K | Form 4 |
| Jul 2, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 2,531 | $34.58 | $87.5K | Form 4 |
| Jul 2, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 1,530 | $35.23 | $53.9K | Form 4 |
| Jul 1, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 739 | $34.06 | $25.2K | Form 4 |
| May 6, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 4,800 | $32.44 | $156K | Form 4 |
| May 6, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 4,800 | $30.07 | $144K | Form 4 |
| Mar 26, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 2,558 | $21.62 | $55.3K | Form 4 |
| Mar 26, 2026 | Rachel McMinn | CEO | Sale plan | 3,352 | $22.07 | $74K | Form 4 |
| Mar 26, 2026 | Julie Jordan | Chief Medical Officer | Sale plan | 828 | $21.89 | $18.1K | Form 4 |
| Mar 13, 2026 | Stuart Cobb | Chief Scientific Officer | Sale plan | 2,658 | $21.34 | $56.7K | Form 4 |
| Mar 13, 2026 | Stuart Cobb | Chief Scientific Officer | Sale plan | 3,991 | $20.41 | $81.5K | Form 4 |
| Mar 13, 2026 | Stuart Cobb | Chief Scientific Officer | Sale plan | 148 | $22.08 | $3.3K | Form 4 |
| Mar 13, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 263 | $22.02 | $5.8K | Form 4 |
| Mar 13, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 1,395 | $21.25 | $29.6K | Form 4 |
| Mar 13, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 2,387 | $20.42 | $48.7K | Form 4 |
| Feb 27, 2026 | Christine Mikail Cvijic | CFO | Sale plan | 4,800 | $25.11 | $121K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Christine Mikail Cvijic | President and CFO | – | $900K | Jul 7, 2026 |
| Stuart Cobb | Chief Scientific Officer | – | $141K | Mar 13, 2026 |
| Rachel McMinn | Chief Executive Officer, Director | – | $74K | Mar 26, 2026 |
| Julie Jordan | Chief Medical Officer | – | $18.1K | Mar 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NGNE short interest
Very high short interest. 28.4% of NGNE shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 58%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.69M NGNE shares were sold short, 28.4% of the shares outstanding, up 11.6% from the report before. At the average daily volume of 335,519 shares, buying them all back would take about 16.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.69M | 28.41% | +12% | 335,519 | 16.9 |
| Oct 15, 2026 | 5.09M | 25.45% | +2% | 354,650 | 14.4 |
| Sep 30, 2026 | 4.97M | 24.86% | +52% | 423,989 | 11.7 |
| Sep 15, 2026 | 3.28M | 16.39% | +5% | 194,657 | 16.9 |
| Aug 31, 2026 | 3.14M | 15.67% | +3% | 230,841 | 13.6 |
| Aug 14, 2026 | 3.04M | 15.18% | +1% | 180,803 | 16.8 |
| Jul 31, 2026 | 3.01M | 19.30% | +3% | 186,066 | 16.1 |
| Jul 15, 2026 | 2.93M | 18.80% | -13% | 386,893 | 7.6 |
| Jun 30, 2026 | 3.35M | 21.52% | -6% | 248,662 | 13.5 |
| Jun 15, 2026 | 3.55M | 22.78% | +0% | 154,684 | 22.9 |
| May 29, 2026 | 3.55M | 22.77% | -2% | 129,045 | 27.5 |
| May 15, 2026 | 3.60M | 23.14% | -3% | 146,197 | 24.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Neurogene company events
Neurogene filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AgreementNeurogene Inc. entered into an underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, as representatives of the underwriters named therein, to issue and sell 3,500,000 shares of the Company’s common stock at a public offering… Filing
- Jun 29, 2026AnnouncementThe Company also made publicly available a presentation announcing positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401gene therapy for the treatment of females with Rett syndrome. Filing
- Jun 8, 2026AnnouncementShared information with investors. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 20, 2026LeadershipThe Board of Directors of Neurogene Inc., upon recommendation of the Board's Nominating and Corporate Governance Committee, took action pursuant to the Company's Amended and Restated Bylaws to expand the Board to seven directors and appoint Christine Mikail, the Company’s President and Chief… Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Feb 26, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Neurogene financials
Famous investors that hold NGNE
4 of the 50 well-known investors we track reported holding NGNE in their latest 13F filing. The largest position is Steve Cohen's, worth $6.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 238,967 | $6.6M | 0.0% | +68% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 92,858 | $2.6M | 0.0% | -77% |
| Israel Englander · Millennium Management | Q3 2026 | 24,633 | $685K | 0.0% | -42% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 10,205 | $284K | 0.0% | -50% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named NGNE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Baker Bros. Advisors LP | 13G/A | 5.0% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 1.5% |
| Nov 16, 2026 | Baker Bros. Advisors LP | 13G/A | 5.0% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 1.5% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 9.3% |
| Nov 16, 2026 | Samsara BioCapital, L.P. | 13G/A | 9.0% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 9.3% |
| Nov 16, 2026 | Samsara BioCapital, L.P. | 13G/A | 9.0% |
| Oct 7, 2026 | PRUDENTIAL FINANCIAL INC | 13G | 11.2% |
| Oct 7, 2026 | PRUDENTIAL FINANCIAL INC | 13G | 11.2% |
| Oct 6, 2026 | Jennison Associates LLC | 13G | 11.1% |
| Oct 6, 2026 | Jennison Associates LLC | 13G | 11.1% |
Questions about Neurogene Inc. (NGNE) stock
Who owns the most NGNE stock?
The largest reported owner of Neurogene Inc. (NGNE) is Samsara Biocapital, LLC, with 11.0% of the company. In total, 113 funds and institutions reported holding NGNE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are NGNE insiders buying or selling?
In the last 12 months, NGNE insiders reported no open-market purchases and 17 sales worth $1.1M. The latest trade was on Jul 7, 2026. See every trade.
What is the short interest in NGNE?
As of Oct 30, 2026, 5.69M NGNE shares were sold short, 28.4% of the shares outstanding, up 11.6% from the report before. At the average daily volume of 335,519 shares, buying them all back would take about 16.9 trading days (days to cover). See the history.
Which famous investors hold NGNE?
4 of the 50 well-known investors we track reported NGNE in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $6.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.